Hybridon Presents New Preclinical Antitumor Data at AACR Supporting its IMOxine Development Program
18 Abril 2005 - 9:05AM
PR Newswire (US)
Hybridon Presents New Preclinical Antitumor Data at AACR Supporting
its IMOxine Development Program Lead Clinical Candidate is a
Toll-like Receptor 9 Agonist CAMBRIDGE, Mass., April 18
/PRNewswire-FirstCall/ -- Hybridon, Inc. (AMEX:HBY) announced today
that it is presenting data from two new preclinical antitumor and
immunopharmacological studies of its lead Phase 2 clinical
candidate IMOxine(R), an agonist of Toll-like receptor 9, at the
96th Annual Meeting of the American Association for Cancer Research
being held in Anaheim, CA, April 16-20, 2005. "The data from these
studies reinforce our belief as to the many potential applications
of our lead oncology drug candidate, IMOxine, in treating cancer as
a monotherapy, in combination therapy, or as part of a
peptide/protein- based cancer vaccine," said Dr. Tim Sullivan, Vice
President of Development Programs at Hybridon, Inc. "IMOxine is
currently in a monotherapy Phase 2 trial in patients with renal
cell carcinoma and we expect to commence a new clinical trial to
evaluate IMOxine in combination with chemotherapy in an additional
cancer indication later this year." The two posters presented are
entitled: i) A second-generation immunomodulatory oligonucleotide
agonist of TLR9 shows antitumor activity and enhances effects of
chemotherapy, radiation and antibody therapy in vitro and in vivo.
Abstract # 720. ii) Synthetic oligonucleotide agonists of Toll-like
receptor 9 enhance immunological responses and antitumor activity
of peptide cancer vaccines. Abstract # 723. Both abstracts are
available on the Company's website http://www.hybridon.com/ .
Studies described in abstract #720 have been done under a research
contract with the University of Alabama at Birmingham. About
IMOxine IMOxine is a 2nd-generation immune modulatory
oligonucleotide (IMO(TM)) that functions as an agonist of Toll-like
Receptor 9 (TLR9), a specific protein receptor in certain cells of
the immune system. Other receptors also may play a role in the
immune system response to IMOxine. TLR9 has been shown to recognize
bacterial DNA and induce a defensive immune response, producing a
Th1-type cytokine profile through activation of dendritic cells and
B lymphocytes. We have studied IMOxine and its murine analogue in a
variety of preclinical tumor models as monotherapy, in combinations
with selected chemotherapeutic agents and monoclonal antibodies,
and with radiation. IMOxine is also known as HYB2055 for Injection.
About Hybridon Hybridon, Inc. is developing novel therapeutics
based on synthetic nucleic acid chemistry for the treatment of
cancer, asthma/allergies, and infectious diseases. Hybridon's
proprietary IMO drug candidates are designed to modulate immune
responses through Toll-like receptors, the body's first line of
defense against disease. The Company's nucleic acid chemistry
expertise has also generated a portfolio of partnered products and
intellectual property, creating the potential for long-term value
for Hybridon. For more information please visit our website at
http://www.hybridon.com/ . This press release contains
forward-looking statements concerning Hybridon that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could
cause Hybridon's actual results to differ materially from those
indicated by such forward-looking statements, including risks as to
whether results obtained in preclinical studies such as the studies
referred to in this release or early clinical trials will be
indicative of results obtained in future preclinical studies or
clinical trials, or warrant further clinical trials and product
development; whether products based on Hybridon's technology will
advance through the clinical trial process and receive approval
from the United States Food and Drug Administration or equivalent
foreign regulatory agencies; whether, if such products receive
approval, they will be successfully distributed and marketed;
whether the patents and patent applications owned or licensed by
Hybridon will protect the Company's technology and prevent others
from infringing it; whether Hybridon's cash resources will be
sufficient to fund product development; whether the Company's
collaborations will be successful; and such other important factors
as are set forth under the caption "Risk Factors" in Hybridon's
Quarterly Report on Form 10-K filed on March 25, 2005, which
important factors are incorporated herein by reference. Hybridon
disclaims any intention or obligation to update any forward-looking
statements. DATASOURCE: Hybridon, Inc. CONTACT: Tim Sullivan of
Hybridon, Inc., +1-617-679-5500, ext. 5526, ; Douglas MacDougall of
MacDougall Biomedical Communications, +1-508-647-0209 ext. 12, ,
for Hybridon, Inc. Web site: http://www.hybridon.com/
Copyright
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024